Literature DB >> 31773491

Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia.

Zhihua Wang1, Lei Yang2, Jing Ye1,3, Yushui Wang1, Yan Liu1.   

Abstract

The aim of this study was to evaluate the changes in the three subsets of monocyte (classical, intermediate, and non-classical) and the expression of human leukocyte antigen-DR (HLA-DR) on monocyte subsets during MP pneumonia in children. Monocyte subsets were analyzed in the peripheral blood of healthy volunteers and MP pneumonia patients at the stages of admission and remission after clinical therapy. They were defined as classical (CD14+CD16-), intermediate (CD14brightCD16+), and non-classical (CD14dimCD16+) using flow cytometry. Furthermore, three subsets of monocyte were analyzed for the expression of HLA-DR. Patients with MP pneumonia at admission had a higher proportion of intermediate and non-classical monocytes than healthy subjects (all P < 0.05). The proportion of intermediate subset and non-classical subset was lower in MP pneumonia patients at remission than at admission (all P < 0.05). In comparison with the other monocyte subsets, intermediate subset showed a significantly higher percentage of HLA-DR in MP pneumonia patients at admission (P < 0.05). Further analysis revealed that the expression of HLA-DR on intermediate subset was lower in severe patients than in non-severe patients (P < 0.05).Our data has shown for the first time that MP pneumonia is associated with the increased proportion of non-classical and intermediate monocytes, indicating the involvement of monocyte-related mechanisms in the pathogenesis of this disease. Additionally, the decreased expression of HLA-DR on CD14brightCD16+ subset may be a potential indicator of the severity of MP pneumonia.

Entities:  

Keywords:  Children; Human leukocyte antigen-DR; Monocyte subsets; Mycoplasma pneumoniae pneumonia

Mesh:

Substances:

Year:  2019        PMID: 31773491     DOI: 10.1007/s12026-019-09096-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  6 in total

1.  Effect of bronchofiberscopic lavage with budesonide suspension on refractory mycoplasma pneumoniae pneumonia.

Authors:  Ya Li; Wei Yang; Xin Wu; Xiaohua Gou
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyan City, China.

Authors:  Long Liu; Xu Lei; Xiao Xiao; Jing Yang; Jian Li; Manshan Ji; Weixing Du; Huabing Tan; Jianyong Zhu; Bei Li; Zhixiong Jin; Weiyong Liu; Jianguo Wu; Zhixin Liu
Journal:  Front Cell Infect Microbiol       Date:  2020-05-22       Impact factor: 5.293

3.  Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study.

Authors:  Chunjiao Han; Tongqiang Zhang; Jiafeng Zheng; Peng Jin; Qi Zhang; Wei Guo; Yongsheng Xu
Journal:  Ital J Pediatr       Date:  2022-08-20       Impact factor: 3.288

4.  Influenza colloidal gold method and blood routine tests combination for rapid diagnosis of influenza: a decision tree-based analysis.

Authors:  Xiaoguang Li; Jing Chen; Fei Lin; Wei Wang; Jie Xu; Nan Li
Journal:  NPJ Prim Care Respir Med       Date:  2021-07-15       Impact factor: 2.871

5.  Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype.

Authors:  Amelia C Trombetta; Guilherme B Farias; André M C Gomes; Ana Godinho-Santos; Pedro Rosmaninho; Carolina M Conceição; Joel Laia; Diana F Santos; Afonso R M Almeida; Catarina Mota; Andreia Gomes; Marta Serrano; Marc Veldhoen; Ana E Sousa; Susana M Fernandes
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 6.  Thrombosis associated with mycoplasma pneumoniae infection (Review).

Authors:  Jingwei Liu; Yumei Li
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.